Parameswaran Venugopal to Treatment Outcome
This is a "connection" page, showing publications Parameswaran Venugopal has written about Treatment Outcome.
Connection Strength
0.481
-
Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma. Br J Haematol. 2017 Apr; 177(1):72-79.
Score: 0.079
-
Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. Leuk Lymphoma. 2015; 56(11):3135-42.
Score: 0.070
-
Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Leuk Lymphoma. 2011 Nov; 52(11):2097-104.
Score: 0.054
-
Recurrent thrombotic thrombocytopenic purpura treated repeatedly and successfully with the monoclonal antibody rituximab. Clin Adv Hematol Oncol. 2006 Mar; 4(3):215-7; discussion 217-8.
Score: 0.037
-
Relapsed non-Hodgkin lymphoma in fraternal twins managed successfully with rituximab maintenance therapy. Clin Adv Hematol Oncol. 2005 Feb; 3(2):136-9; discussion 139-40.
Score: 0.034
-
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer. 2021 12 01; 127(23):4421-4431.
Score: 0.027
-
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood. 2021 01 21; 137(3):374-386.
Score: 0.026
-
Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. Br J Haematol. 2019 07; 186(1):45-53.
Score: 0.023
-
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
Score: 0.023
-
Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20. Chemotherapy. 2017; 62(2):140-146.
Score: 0.020
-
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015 Apr 10; 33(11):1252-7.
Score: 0.017
-
Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2012 Feb; 10(2):134-6.
Score: 0.014
-
GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas. Leuk Lymphoma. 2008 Sep; 49(9):1681-92.
Score: 0.011
-
Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007 May; 7(6):406-12.
Score: 0.010
-
Posttransplant lymphoproliferative disorder: extranodal marginal zone lymphoma occurring after renal transplantation. Clin Adv Hematol Oncol. 2006 Aug; 4(8):600-4; discussion 604-6.
Score: 0.010
-
Durable remission of intravascular lymphoma with central nervous system involvement following chemotherapy and rituximab. Clin Adv Hematol Oncol. 2006 Jun; 4(6):439-41.
Score: 0.009
-
The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma. Clin Lymphoma. 2005 Jun; 6(1):26-30.
Score: 0.009
-
Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma. Clin Adv Hematol Oncol. 2004 Apr; 2(4):229-33.
Score: 0.008